Vividion Therapeutics, Inc.
https://vividion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vividion Therapeutics, Inc.
Women’s Health Still Key to Bayer Despite Early Research Shift
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.
No Slowdown From Bayer On Business Development Front
“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Five Challenges Bill Anderson Faces At Bayer
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice